The expression of oncogenes in cancer cells can affect susceptibility to PDT, while tumor cell selectivity can be increased by equipping the PS with a delivery system containing a targeting component—in this case, an NGR peptide specific to aminopeptidase N (APN; CD13). This evidence concerns the gene RTN4R and cancer.